
1. Antiviral Res. 2021 Nov 24;197:105212. doi: 10.1016/j.antiviral.2021.105212.
[Epub ahead of print]

Hydroxychloroquine and azithromycin used alone or combined are not effective
against SARS-CoV-2 ex vivo and in a hamster model.

Cochin M(1), Touret F(2), Driouich JS(2), Moureau G(2), Petit PR(2), Laprie C(3),
Solas C(4), de Lamballerie X(2), Nougairède A(5).

Author information: 
(1)Unité des Virus Émergents, UVE: Aix Marseille Université, IRD 190, INSERM
1207, Marseille, France. Electronic address: maxime.cochin@univ-amu.fr.
(2)Unité des Virus Émergents, UVE: Aix Marseille Université, IRD 190, INSERM
1207, Marseille, France.
(3)Laboratoire Vet-Histo, Marseille, France.
(4)Unité des Virus Émergents, UVE: Aix Marseille Université, IRD 190, INSERM
1207, Marseille, France; Laboratoire de Pharmacocinétique et Toxicologie, Hôpital
La Timone, APHM, Marseille, France.
(5)Unité des Virus Émergents, UVE: Aix Marseille Université, IRD 190, INSERM
1207, Marseille, France. Electronic address: antoine.nougairede@univ-amu.fr.

Drug repositioning has been used extensively since the beginning of the COVID-19 
pandemic in an attempt to identify antiviral molecules for use in human
therapeutics. Hydroxychloroquine and azithromycin have shown inhibitory activity 
against SARS-CoV-2 replication in different cell lines. Based on such in vitro
data and despite the weakness of preclinical assessment, many clinical trials
were set up using these molecules. In the present study, we show that
hydroxychloroquine and azithromycin alone or combined does not block SARS-CoV-2
replication in human bronchial airway epithelia. When tested in a Syrian hamster 
model, hydroxychloroquine and azithromycin administrated alone or combined
displayed no significant effect on viral replication, clinical course of the
disease and lung impairments, even at high doses. Hydroxychloroquine
quantification in lung tissues confirmed strong exposure to the drug, above in
vitro inhibitory concentrations. Overall, this study does not support the use of 
hydroxychloroquine and azithromycin as antiviral drugs for the treatment of
SARS-CoV-2 infections.

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

DOI: 10.1016/j.antiviral.2021.105212 
PMCID: PMC8611861
PMID: 34838583 

